Synektik S.A. Asset Resilience Ratio
Synektik S.A. asset resilience ratio. Synektik S.A. (SNT) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SNT total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Synektik S.A. (2012–2025)
Asset resilience ratio of Synektik S.A. from 2012 to 2025. This chart shows how Synektik S.A.'s Asset Resilience Ratio has changed over time. See Synektik S.A. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Synektik S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Synektik S.A. (SNT) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł1.31K | 0.0% |
| Total Liquid Assets | zł1.31K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Synektik S.A. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Synektik S.A. Industry Peers by Asset Resilience Ratio
Compare Synektik S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
SIEMENS HEALTH ADR/050
F:SHL1 |
Medical Devices | 1.05% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Wellell Inc
TW:4106 |
Medical Devices | 2.43% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 15.99% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
Synektik S.A. Asset Resilience Ratio by Year (2012–2025)
Synektik S.A. asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Synektik S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | zł1.31K ≈ $361.87 |
zł489.11 Million ≈ $134.61 Million |
-0.27pp |
| 2023-12-31 | 0.27% | zł802.49K ≈ $220.86K |
zł299.92 Million ≈ $82.54 Million |
-0.23pp |
| 2022-12-31 | 0.50% | zł1.18 Million ≈ $324.29K |
zł236.48 Million ≈ $65.08 Million |
+3.52pp |
| 2021-12-31 | -3.02% | zł-4.83 Million ≈ $-1.33 Million |
zł159.69 Million ≈ $43.95 Million |
+1.75pp |
| 2020-12-31 | -4.77% | zł-6.76 Million ≈ $-1.86 Million |
zł141.61 Million ≈ $38.97 Million |
-1.32pp |
| 2019-12-31 | -3.46% | zł-4.33 Million ≈ $-1.19 Million |
zł125.10 Million ≈ $34.43 Million |
-3.07pp |
| 2018-12-31 | -0.39% | zł-421.39K ≈ $-115.97K |
zł108.59 Million ≈ $29.88 Million |
-0.39pp |
| 2016-12-31 | 0.00% | zł-1.50K ≈ $-412.82 |
zł90.75 Million ≈ $24.98 Million |
+0.08pp |
| 2015-12-31 | -0.08% | zł-85.07K ≈ $-23.41K |
zł104.40 Million ≈ $28.73 Million |
-0.08pp |
| 2014-12-31 | 0.00% | zł-1.50K ≈ $-412.82 |
zł106.79 Million ≈ $29.39 Million |
-0.83pp |
| 2012-12-31 | 0.83% | zł511.96K ≈ $140.90K |
zł61.56 Million ≈ $16.94 Million |
-- |
About Synektik S.A.
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics … Read more